NCT03979638

A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough

A Randomized, Double-Blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects With Unexplained or Refractory Chronic Cough (RELIEF)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 68 (actual)
• Sponsor: Bellus Health Inc. - a GSK company · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, crossover, dose escalation study of BLU-5937 in subjects with unexplained or refractory chronic cough

Detailed description

This study will have two 16-day treatment periods (four escalating doses or matching placebo at four days interval) separated by a 10 to 14-day washout period. There will be a 14-day follow-up period.

Conditions

• Chronic Refractory Cough

Interventions

Type	Name	Description
DRUG	BLU-5937	Four escalating doses of BLU-5937 administered BID over the course of the study
DRUG	Placebo	Matching placebo for BLU-5937

Timeline

• Start date: 2019-07-10
• Primary completion: 2020-04-23
• Completion: 2020-04-23
• First posted: 2019-06-07
• Last updated: 2021-08-03
• Results posted: 2021-08-03

Locations

16 sites across 2 countries: United States, United Kingdom

Regulatory

• FDA-regulated drug study